HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Alpha Tau Medical (NASDAQ:DRTS) and maintained a price target of $9.
September 20, 2023 | 10:38 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alpha Tau Medical's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $9.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $9 indicates the firm's confidence in the stock's potential to reach this price, which could drive investor interest and potentially increase the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100